In this report, we show that pancreatic cancer cells that develop resistance to BET inhibitors upregulate GLI2 and that targeting GLI2 re-sensitizes the pancreatic cancer cells to BET inhibitors. This evidence concerns the gene GLI2 and pancreatic neoplasm.